Skip to main content
SpringerLink
Log in

Le mésothéliome pleural malin

Malignant pleural mesothelioma

  • Mise au Point / Update
  • Published:
Oncologie

Résumé

Le mésothéliome pleural malin (MPM) est une tumeur rare et agressive, souvent consécutive à une exposition professionnelle à l’amiante. La symptomatologie clinique et radiologique est aspécifique. Le diagnostic est apporté par l’histologie à partir de biopsies pleurales obtenues par thoracoscopie. L’irradiation des orifices chirurgicaux diagnostiques est validée par les recommandations francophones. La chirurgie par pleuropneumonectomie élargie ou par pleurectomie/décortication n’est pas recommandée en dehors d’un essai clinique. La chimiothérapie par la combinaison pemetrexed-cisplatine est le traitement de référence du MPM. Le bevacizumab est évalué dans l’essai de phase III MAPS dont les 445 inclusions se sont terminées en décembre 2013.

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive tumor, secondary to occupational asbestos exposure. Clinical and radiological signs are unspecific. The diagnosis of MPM is based on histology and on biopsies best obtained by thoracoscopy. Prophylactic irradiation of chest scars and drains is validated by French guidelines. Surgery, extrapleural pneumonectomy or pleurectomy/decortication is not recommended outside a clinical trial. Firstline chemotherapy with pemetrexed remains the standard treatment. Bevacizumab was tested in an randomized phase 3 trial, MAPS, until December 2013.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Références

  1. Wagner JC, Sleggs CA, Marchand P (1960) Diffuse pleural mesothelioma ans asbestosis exposure in the North Western Cape Province. Br J Ind Med 17: 260–271

    CAS  PubMed Central  PubMed  Google Scholar 

  2. Margery J, Ruffié P (2008) Environmental cancer: malignant pleural mesothelioma. Bull Cancer 95: 77–86

    CAS  PubMed  Google Scholar 

  3. Peto J, Decarli A, La Vecchia C, et al. (1999) The European mesothelioma epidemic. Br J Cancer 79: 666–672

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Goldberg M, Imbernon E, Rolland P, et al. (2006) The French National Mesothelioma Surveillance Program. Occup Environ Med 63: 390–395

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Le Stang N, Belot A, Gilg Soit Ilg A, et al. (2010) Evolution of pleural cancers and malignant pleural mesothelioma incidence in France between 1980 and 205. Int J Cancer 126: 232–238

    Article  PubMed  Google Scholar 

  6. Scherpereel A, French speaking Society for Chest Medicine Experts Group (2007) Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma. Respir Med 101: 1265–1276

    Article  PubMed  Google Scholar 

  7. Scherpereel A, Astoul P, Baas P, et al. (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35: 479–495

    Article  CAS  PubMed  Google Scholar 

  8. Scherpereel A, Lee YCG (2007) Biomarkers for mesothelioma. Curr Opin Pulm Med 13: 339–343

    Article  CAS  PubMed  Google Scholar 

  9. Bianchi AB, Mitsunaga SI, Sheng JQ, et al. (1995) High frequency of inactivating mutations in the neurofibromatosis type 2 (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A 92: 10854–10858

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  10. Wong L, Zhou J, Anderson D, Kratzke RA (2002) Inactivation of p16INK4a expression in malignant pleural mesothelioma by methylation. Lung Cancer 38: 131–136

    Article  PubMed  Google Scholar 

  11. Coll GW Jr, Alleva AM, Zuo JT, et al. (2006) Suppression of prometastasis phenotypes expression in malignant pleural mesothelioma by the PI3K inhibitor LY294002 of the MEK inhibitor UO126. Anticancer Res 26: 809–821

    Google Scholar 

  12. Fox S, Dharmarajan A (2006) Wnt signalling in malignant mesothelioma. Front Biosci 11: 2106–2112

    Article  CAS  PubMed  Google Scholar 

  13. Levallet G, Vaisse-Lesteven M, Le Stang N, et al. (2012) Plasma cell membrane localization of c-Met predicts longer survival in patients with malignant mesothelioma: a serie of 157 cases from the MESOPATH Group. J Thorac Oncol 7: 599–606

    Article  PubMed  Google Scholar 

  14. Bott M, Brevet M, Taylor BS, et al. (2011) The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p.21.1 losses in malignant pleural mesothelioma. Nat Genet 43: 668–672

    Article  CAS  PubMed  Google Scholar 

  15. Testa JR, Cheung M, Pei J, et al. (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43: 1022–1025

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  16. Rusch VW, Giroux D, Kennedy C, et al. (2012) Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol 7: 1631–1639

    Article  PubMed  Google Scholar 

  17. Damhuis RA, Schroten C, Burgers JA (2012) Population-based survival for malignant mesothelioma after introduction of novel chemotherapy. Eur Respir J 40: 185–189

    Article  PubMed  Google Scholar 

  18. Fennell DA, Parmar A, Shamash J, et al. (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23: 184–189

    Article  PubMed  Google Scholar 

  19. Sharif S, Zahid I, Routledge T, Scarci M (2011) Does positron emission tomography offer prognostic information in malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg 12: 806–811

    Article  PubMed  Google Scholar 

  20. Boutin C, Rey F, Viallat JR (1995) Prevention of malignant seeding after invasive procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy. Chest 108: 754–758

    Article  CAS  PubMed  Google Scholar 

  21. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636–2644

    Article  CAS  PubMed  Google Scholar 

  22. Ceseroli GL, Castagneto B, Zucali PA, et al. (2008) Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 99: 51–56

    Article  Google Scholar 

  23. Van den Bogaert D, Pouw EM, Van Wijhe G, et al. (2006) Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol 1: 25–30

    Article  PubMed  Google Scholar 

  24. Kindler HL, Karrison TG, Gandara DR, et al. (2012) Multicenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma. J Clin Oncol 30: 2509–2515

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  25. Margery J, Rivière F, Planchard D, et al. (2010) Second-line therapy in patients with pleural malignant mesothelioma. A French retrospective study (2005–2006). Rev Pneumol Clin 66: 255–259

    Article  CAS  PubMed  Google Scholar 

  26. Zucali PA, Simonelli M, Michetti G, et al. (2012) Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey. Lung Cancer 75: 360–367

    Article  CAS  PubMed  Google Scholar 

  27. Scherpereel A, Berghmans T, Lafitte JJ, et al. (2011) Valproate-doxorubicin: a promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 37: 129–135

    Article  CAS  PubMed  Google Scholar 

  28. Cao CQ, Yan TD, Bannon PG, McCaughan BC (2010) A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Oncol 5: 1692–1703

    Article  PubMed  Google Scholar 

  29. Treasure T, Internullo E, Fiorentino F, et al. (2011) A survey of opinions and beliefs concerning surgery for malignant pleural mesothelioma amongst 802 members of the European Association for Cardio-Thoracic Surgery (EACTS), the European Society of Thoracic Surgeons (ESTS) and the Society of Thoracic Surgeons (STS). Interact Cardiovasc Thorac Surg 12: 341–346

    Article  PubMed  Google Scholar 

  30. Van Schil PE, Baas P, Gaafar R, et al. (2010) Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 36: 1362–1369

    Article  PubMed  Google Scholar 

  31. Treasure T, Lang-Lazdunski L, Waller D, et al. (2012) Extrapleural pneumonectomy versus non extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the mesothelioma and radical surgery (MARS) randomized feasibility study. Lancet Oncol 12: 763–772

    Article  Google Scholar 

  32. Flores RM, Zakowski M, Venkatraman E, et al. (2007) Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol 2: 957–965

    Article  PubMed  Google Scholar 

  33. Ray M, Kindler HL (2009) Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888–896

    Article  PubMed  Google Scholar 

  34. Friedberg JS, Myck C, Cullingan M, et al. (2011) Photodynamic therapy and the evolution of a lung-sparing surgical treatment for mesothelioma. Ann Thorac Surg 91: 1738–1745

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de pneumologie, HIA Percy, 101, avenue Henri-Barbusse, F-92140, Clamart, France

    J. Margery

  2. Département de médecine, Gustave-Roussy, 114, Rue Édouard Vaillant, F-94805, Villejuif, France

    D. Planchard

Authors
  1. J. Margery
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Planchard
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J. Margery.

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Margery, J., Planchard, D. Le mésothéliome pleural malin. Oncologie 16, 245–249 (2014). https://doi.org/10.1007/s10269-014-2395-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10269-014-2395-x

Mots clés

Keywords

Search

Navigation